Although Soleno’s primary endpoint for DCCR in PWS relates to hyperphagia (constant hunger), and it will be approved (or not) on that basis, there is clinical evidence that suggests that DCCR can also positively impact aggression, anxiety, compulsivity/rigidity, depression and disordered thinking.
And although Acadia’s proposed intranasal carbetocin treatment for PWS also targets hyperphagia as its primary endpoint, there is clinical evidence that suggests that carbetocin can also be beneficial for anxiousness and distress.
As for concerns that Soleno’s or Acadia’s drug, or NNZ-2591, might be “abused” by those seeking weight loss – I would think that a high list price will prevent that.
Without insurance, Ozempic costs ~ A$15,000 per year. For wealthy, non-diabetic people seeking substantial weight loss, of which there are many in this world, that’s doable. Hence Jimmy Kimmel’s joke at the Oscars suggesting that most of the audience was using Ozempic.
But if, for example, a 50+kg adult wanted to use DayBue off-label, the cost per annum would be A$1.3m. A significant deterrent!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10271225/
- Forums
- ASX - By Stock
- NEU
- PHASE2 PRADER WILLI SYNDROME START !!!!
PHASE2 PRADER WILLI SYNDROME START !!!!, page-43
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.02 |
Change
-0.540(3.71%) |
Mkt cap ! $1.806B |
Open | High | Low | Value | Volume |
$14.38 | $14.42 | $13.94 | $3.912M | 276.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 209 | $14.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.03 | 858 | 23 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5 | 14.040 |
9 | 760 | 14.030 |
4 | 519 | 14.020 |
5 | 699 | 14.010 |
6 | 2373 | 14.000 |
Price($) | Vol. | No. |
---|---|---|
14.050 | 332 | 7 |
14.060 | 1440 | 10 |
14.070 | 1225 | 6 |
14.080 | 636 | 4 |
14.090 | 864 | 4 |
Last trade - 15.14pm 04/10/2024 (20 minute delay) ? |
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEU (ASX) Chart |